Stockreport

Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation

Mesoblast Limited - American Depositary Shares  (MESO) 
US:NASDAQ Investor Relations: investorsmedia.mesoblast.com
PDF Mesoblast outlines commercial strategy to double net revenues as Ryoncil® approaches US$100M net revenue milestone since launch last year Showcases transformative bloc [Read more]